[The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma]

Area of Science:

• Hematology
• Immunology
• Oncology

Context:

• CD138 is a marker typically highly expressed on multiple myeloma cells.
• A reduction in CD138 positive cells has been observed in some patients during therapy.
• The clinical significance of this reduction remains unclear.

Purpose:

• To investigate the clinical significance of CD138 expression dynamics during multiple myeloma treatment.
• To correlate CD138 levels with laboratory data and patient outcomes using flow cytometry.

Summary:

• CD138 positive cells decreased in 12 out of 117 multiple myeloma patients during treatment.
• Patients with reduced CD138+ cells showed a median survival of 25 months, with 75% dying from myeloma.
• Associated findings in the reduced CD138+ group included extramedullary lesions and adverse cytogenetic abnormalities.
• A re-increase in CD138+ levels was observed in 2 of 3 long-term survivors.

Impact:

• The reduction in CD138+ cells may suggest a poor prognosis and potential drug resistance in multiple myeloma.
• Sustained low CD138+ levels without re-increase might indicate difficulties in achieving long-term survival.
• Monitoring CD138 expression dynamics could offer insights into treatment response and patient prognosis.